ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
BLRX Company Profile and Key Details
BioLineRx Ltd.
Price Chart
Stock Price Today
BioLineRx Ltd. (BLRX) stock declined over -1.03%, trading at $2.87 on NASDAQ, down from the previous close of $2.90. The stock opened at $2.95, fluctuating between $2.84 and $2.95 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
Annual Report (10-k)
Stock Price History Chart
Contact Details
About Company
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Company Information
| Employees | 28 |
| Beta | 0.95 |
| Sales or Revenue | $4.80M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Chief Medical Officer
Mr. Adam Janoff Esq.
Gen. Counsel & Head of Compliance
Ms. Mali Zeevi CPA, CPA
Chief Financial Officer
Advocate Norman Kotler
Internal Enforcement Officer, Gen. Counsel and Corporation Sec.
Ms. Holly W. May M.B.A.
Pres of BioLineRx USA
Mr. Raziel Fried
Treasurer & Budgetary Control Director
Dr. Ella Sorani
Chief Devel. Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Executive Officer
Mr. John Lacey
Head of Corporation Communications & Investor Relations
Ms. Jael Birenberg M.Sc.
Senior Director & Head of RA, QA and PhV
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.
Head of BD & Strategic Advisor
Ms. Liron Shemesh-Darvish M.B.A., Ph.D.
Senior Director & Head of Preclinical Devel.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep